Literature DB >> 7545156

Expression of Shigella dysenteriae serotype 1 O-antigenic polysaccharide by Shigella flexneri aroD vaccine candidates and different S. flexneri serotypes.

I C Fält1, E K Schweda, S Klee, M Singh, E Floderus, K N Timmis, A A Lindberg.   

Abstract

The potential utility of Shigella flexneri aroD vaccine candidates for the development of bi- or multivalent vaccines has been explored by the introduction of the genetic determinants rfp and rfb for heterologous O antigen polysaccharide from Shigella dysenteriae serotype 1. The serotype Y vaccine strain SFL124 expressed the heterologous antigen qualitatively and quantitatively well, qualitatively in the sense of the O antigen polysaccharide being correctly linked to the S. flexneri lipopolysaccharide R3 core oligosaccharide and quantitatively in the sense that typical yields were obtained, with ratios of homologous to heterologous O antigen being 4:1 for one construct and 1:1 for another. Moreover, both polysaccharide chains were shown to be linked to position O-4 of the subterminal D-glucose residue of the R3 core. In contrast to the hybrid serotype Y SFL124 derivatives, analogous derivatives of serotype 2a vaccine strain SFL1070 did not elaborate a complete heterologous O antigen. Such derivatives, and analogous derivatives of rough, O antigen-negative mutants of SFL1070, formed instead a hybrid lipopolysaccharide molecule consisting of the S. flexneri lipid A R3 core with a single repeat unit of the S. dysenteriae type 1 O antigen. Introduction of the determinants for the S. dysenteriae type 1 O antigen into a second serotype 2a strain and into strains representing other serotypes of S. flexneri, revealed the following for the expression of the heterologous O antigen: serotypes 1a, 1b, 2a, and 5a did not produce the heterologous O antigen, whereas serotypes 2b, 3a, 3b, 4a, 4b, 5b, and X did.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7545156      PMCID: PMC177324          DOI: 10.1128/jb.177.18.5310-5315.1995

Source DB:  PubMed          Journal:  J Bacteriol        ISSN: 0021-9193            Impact factor:   3.490


  23 in total

1.  Increased resolution of lipopolysaccharides and lipooligosaccharides utilizing tricine-sodium dodecyl sulfate-polyacrylamide gel electrophoresis.

Authors:  A J Lesse; A A Campagnari; W E Bittner; M A Apicella
Journal:  J Immunol Methods       Date:  1990-01-24       Impact factor: 2.303

2.  Cloning of the rfb gene region of Shigella dysenteriae 1 and construction of an rfb-rfp gene cassette for the development of lipopolysaccharide-based live anti-dysentery vaccines.

Authors:  S Sturm; K N Timmis
Journal:  Microb Pathog       Date:  1986-06       Impact factor: 3.738

3.  Genetic and biochemical analysis of Shigella dysenteriae 1 O antigen polysaccharide biosynthesis in Escherichia coli K-12: structure and functions of the rfb gene cluster.

Authors:  S Sturm; B Jann; K Jann; P Fortnagel; K N Timmis
Journal:  Microb Pathog       Date:  1986-06       Impact factor: 3.738

4.  Basic structure of the oligosaccharide repeating-unit of the Shigella flexneri O-antigens.

Authors:  L Kenne; B Lindberg; K Petersson
Journal:  Carbohydr Res       Date:  1977-07       Impact factor: 2.104

5.  Interposon mutagenesis of soil and water bacteria: a family of DNA fragments designed for in vitro insertional mutagenesis of gram-negative bacteria.

Authors:  R Fellay; J Frey; H Krisch
Journal:  Gene       Date:  1987       Impact factor: 3.688

6.  Detection and differentiation of iron-responsive avirulent mutants on Congo red agar.

Authors:  S M Payne; R A Finkelstein
Journal:  Infect Immun       Date:  1977-10       Impact factor: 3.441

7.  Morphological heterogeneity among Salmonella lipopolysaccharide chemotypes in silver-stained polyacrylamide gels.

Authors:  P J Hitchcock; T M Brown
Journal:  J Bacteriol       Date:  1983-04       Impact factor: 3.490

8.  Structural studies on the hexose region of the core in lipopolysaccharides from Enterobacteriaceae.

Authors:  P E Jansson; A A Lindberg; B Lindberg; R Wollin
Journal:  Eur J Biochem       Date:  1981-04

Review 9.  Development of an auxotrophic oral live Shigella flexneri vaccine.

Authors:  A A Lindberg; A Kärnell; B A Stocker; S Katakura; H Sweiha; F P Reinholt
Journal:  Vaccine       Date:  1988-04       Impact factor: 3.641

10.  Monoclonal antibodies specific for Shigella flexneri lipopolysaccharides: clones binding to type IV, V, and VI antigens, group 3,4 antigen, and an epitope common to all Shigella flexneri and Shigella dysenteriae type 1 stains.

Authors:  N I Carlin; A A Lindberg
Journal:  Infect Immun       Date:  1987-06       Impact factor: 3.441

View more
  5 in total

1.  Construction and characterization of a live attenuated vaccine candidate against Shigella dysenteriae type 1.

Authors:  S R Klee; B D Tzschaschel; I Fält; A Kärnell; A A Lindberg; K N Timmis; C A Guzmán
Journal:  Infect Immun       Date:  1997-06       Impact factor: 3.441

2.  Construction, characterization, and animal testing of WRSd1, a Shigella dysenteriae 1 vaccine.

Authors:  Malabi M Venkatesan; Antoinette B Hartman; John W Newland; Vessela S Ivanova; Thomas L Hale; Marie McDonough; Joan Butterton
Journal:  Infect Immun       Date:  2002-06       Impact factor: 3.441

3.  Influence of different rol gene products on the chain length of Shigella dysenteriae type 1 lipopolysaccharide O antigen expressed by Shigella flexneri carrier strains.

Authors:  S R Klee; B D Tzschaschel; K N Timmis; C A Guzman
Journal:  J Bacteriol       Date:  1997-04       Impact factor: 3.490

4.  Production of glycoprotein vaccines in Escherichia coli.

Authors:  Julian Ihssen; Michael Kowarik; Sandro Dilettoso; Cyril Tanner; Michael Wacker; Linda Thöny-Meyer
Journal:  Microb Cell Fact       Date:  2010-08-11       Impact factor: 5.328

5.  Physiological stress of intracellular Shigella flexneri visualized with a metabolic sensor fused to a surface-reporter system.

Authors:  Carlos A Guzmán; Angel Cebolla; Fabricio Beltrametti; Lothar H Staender; Víctor de Lorenzo
Journal:  FEBS Lett       Date:  2005-01-31       Impact factor: 4.124

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.